<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465216</url>
  </required_header>
  <id_info>
    <org_study_id>IDRI-TBVPX-203</org_study_id>
    <nct_id>NCT02465216</nct_id>
  </id_info>
  <brief_title>Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion</brief_title>
  <official_title>A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in HIV Uninfected Adult TB Patients After Treatment Completion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDRI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South African Tuberculosis Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IDRI</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of ID93 + GLA-SE
      vaccine when administered to adult pulmonary Tuberculosis (TB) patients, following successful
      completion of TB treatment with confirmed bacteriologic cure, in preparation for a future
      Phase 2b prevention of TB recurrence trial in the same population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>224 days</time_frame>
    <description>Safety outcomes will include solicited adverse events within 7 days and unsolicited adverse events within 28 days after each study injection; and serious adverse events after the first study injection until end of study follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Responder Rate</measure>
    <time_frame>Day 70</time_frame>
    <description>Immunogenicity will be evaluated by measuring humoral and cellular responses to ID93 + GLA-SE at Day 70.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>2 mcg ID93 + 2 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mcg ID93 + 2 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mcg ID93 + 5 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ID93 + GLA-SE</intervention_name>
    <description>ID93 + GLA-SE</description>
    <arm_group_label>10 mcg ID93 + 2 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_label>2 mcg ID93 + 2 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_label>2 mcg ID93 + 5 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_label>2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females 18 to 60 years of age.

          2. Subjects must have been successfully treated, i.e., completed the scheduled course of
             TB treatment as per the prevailing South African national guidelines, for MTB
             culture-confirmed, drug sensitive pulmonary TB, as evidenced by a record of positive
             liquid MTB culture with formal drug sensitivity testing (DST) and/or by Xpert MTB/RIF
             test at baseline.

          3. Must have two separate samples showing bacteriologic confirmation of cure - defined in
             the first instance as Xpert MTB/RIF test negative, or, if Xpert MTB/RIF positive, as
             MTB liquid culture negative - on two successive occasions at least 30 days apart.
             Subjects who are sputum unproductive will be deemed Xpert MTB/RIF and MTB liquid
             culture negative.

          4. Female subjects of childbearing potential must have a negative serum pregnancy test at
             screening and a negative urine pregnancy test on the day of each study injection, must
             not be breast-feeding, and be willing to avoid pregnancy for 3 months following first
             study injection. Women physically capable of pregnancy (not sterilized and still
             menstruating or within 1 year of the last menses if menopausal) in sexual
             relationships with men must use an acceptable method of avoiding pregnancy during this
             period. Acceptable methods of avoiding pregnancy include a sterile sexual partner,
             sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral,
             injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or
             the combination of a condom or diaphragm with spermicide gel.

          5. The following screening laboratory values must be within the laboratory reference
             range or, if abnormal, deemed not clinically significant and less than Grade 2
             severity on the FDA Toxicity Scale, as determined by the PI and LMM or Sponsor Medical
             Advisor: ALT, AST, total bilirubin, creatinine, total WBC count, hemoglobin, and
             platelet count.

          6. The HIV 1/2 antibody serology tests must be negative.

          7. Must give informed consent, be able and willing to make all evaluation visits, be
             reachable by telephone or personal contact by the study site personnel, and be willing
             to remain in the study area for the duration of the trial.

        Exclusion Criteria:

          1. TB treatment failure, as evidenced by clinical diagnosis or a positive MTB liquid
             culture at month 4 or 5 after starting treatment. A positive MTB liquid culture at, or
             after, end of treatment would exclude subjects from receiving further study
             injections.

          2. Previous course of TB treatment completed within 5 calendar years prior to obtaining
             baseline diagnostic sputum samples.

          3. Receipt of any investigational products or investigational drug in the past 6 months
             or investigational vaccine ever.

          4. Treatment with immunosuppressive drugs (e.g., oral or injected steroids, such as
             prednisone; high dose inhaled steroids) in the past 6 months. Topical steroids would
             be allowable.

          5. Received incomplete or investigational, or non-standard TB drug regimen, other than
             the prevailing current South African national guideline as reference standard, or poor
             adherence to TB treatment regimen.

          6. Diagnosed with rifampicin-resistant MTB strain (by Xpert MTB/RIF and/or culture and
             formal DST).

          7. History of autoimmune disease or other causes of immunosuppressive states.

          8. History or evidence of any acute or chronic illness (including diabetes mellitus,
             asthma), medical or surgical condition, or chronic heavy ethanol or drug use, or use
             of medication that, in the opinion of the Principal Investigator, may interfere with
             the evaluation of the safety or immunogenicity of the vaccine.

          9. Subjects with a history of previous anaphylaxis or severe allergic reaction to
             vaccines, eggs, or unknown allergens.

         10. Subjects who are unlikely to cooperate with the requirements of the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Hatherill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South African Tuberculosis Vaccine Initiative</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TASK Applied Sciences</name>
      <address>
        <city>Cape Town</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Centre (DTHC)</name>
      <address>
        <city>Cape Town</city>
        <zip>7750</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South African Tuberculosis Vaccine Initiative (SATVI)</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <results_first_submitted>October 11, 2018</results_first_submitted>
  <results_first_submitted_qc>October 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2018</results_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>TB</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2 mcg ID93 + 2 mcg GLA-SE Vaccine</title>
          <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="P2">
          <title>10 mcg ID93 + 2 mcg GLA-SE Vaccine</title>
          <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="P3">
          <title>2 mcg ID93 + 5 mcg GLA-SE Vaccine</title>
          <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="P4">
          <title>2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 Doses</title>
          <description>Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2 mcg ID93 + 2 mcg GLA-SE Vaccine</title>
          <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="B2">
          <title>10 mcg ID93 + 2 mcg GLA-SE Vaccine</title>
          <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="B3">
          <title>2 mcg ID93 + 5 mcg GLA-SE Vaccine</title>
          <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="B4">
          <title>2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 Doses</title>
          <description>Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
Placebo: Placebo</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.6" spread="2.32"/>
                    <measurement group_id="B2" value="22.8" spread="5.4"/>
                    <measurement group_id="B3" value="19.6" spread="2.38"/>
                    <measurement group_id="B4" value="21.4" spread="4.92"/>
                    <measurement group_id="B5" value="21.4" spread="1.94"/>
                    <measurement group_id="B6" value="20.9" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events</title>
        <description>Safety outcomes will include solicited adverse events within 7 days and unsolicited adverse events within 28 days after each study injection; and serious adverse events after the first study injection until end of study follow-up.</description>
        <time_frame>224 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mcg ID93 + 2 mcg GLA-SE Vaccine</title>
            <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
          </group>
          <group group_id="O2">
            <title>10 mcg ID93 + 2 mcg GLA-SE Vaccine</title>
            <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
          </group>
          <group group_id="O3">
            <title>2 mcg ID93 + 5 mcg GLA-SE Vaccine</title>
            <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
ID93 + GLA-SE: ID93 + GLA-SE</description>
          </group>
          <group group_id="O4">
            <title>2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 Doses</title>
            <description>Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>Safety outcomes will include solicited adverse events within 7 days and unsolicited adverse events within 28 days after each study injection; and serious adverse events after the first study injection until end of study follow-up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local Injection Site Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Systemic Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Responder Rate</title>
        <description>Immunogenicity will be evaluated by measuring humoral and cellular responses to ID93 + GLA-SE at Day 70.</description>
        <time_frame>Day 70</time_frame>
        <population>Those participants without major protocol deviations and with samples available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mcg ID93 + 2 mcg GLA-SE Vaccine</title>
            <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
          </group>
          <group group_id="O2">
            <title>10 mcg ID93 + 2 mcg GLA-SE Vaccine</title>
            <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
          </group>
          <group group_id="O3">
            <title>2 mcg ID93 + 5 mcg GLA-SE Vaccine</title>
            <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
ID93 + GLA-SE: ID93 + GLA-SE</description>
          </group>
          <group group_id="O4">
            <title>2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 Doses</title>
            <description>Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Responder Rate</title>
          <description>Immunogenicity will be evaluated by measuring humoral and cellular responses to ID93 + GLA-SE at Day 70.</description>
          <population>Those participants without major protocol deviations and with samples available for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgG antibody responder rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T cell responder rate (whole antigen stim)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>224 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>2 mcg ID93 + 2 mcg GLA-SE Vaccine</title>
          <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="E2">
          <title>10 mcg ID93 + 2 mcg GLA-SE Vaccine</title>
          <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="E3">
          <title>2 mcg ID93 + 5 mcg GLA-SE Vaccine</title>
          <description>Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="E4">
          <title>2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 Doses</title>
          <description>Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
ID93 + GLA-SE: ID93 + GLA-SE</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Chest wall tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" events="16" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E4" events="13" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>URTI</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>WBC count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>WBC count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Corey Casper</name_or_title>
      <organization>IDRI</organization>
      <phone>2063810883</phone>
      <email>corey.casper@idri.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

